EIF2AK4 and colorectal carcinoma: Recently, approaches for developing optimized GCN2 inhibitors, including compounds that contain the triazolo [4,5-d] pyrimidine core, have been investigated; some of these small molecules exert anti-proliferative activity in CRC cells [202,203,204].